Cytokinesis, the final step of mitosis, is critical for maintaining the ploidy level of cells. Cytokinesis is a complex, highly regulated process and its failure can lead to genetic instability and apoptosis, contributing to the development of cancer. Human hepatocellular carcinoma is often accompanied by a high frequency of aneuploidy and the DNA ploidy pattern observed in human hepatocellular carcinoma results mostly from impairments in cytokinesis. Many key regulators of cytokinesis are abnormally expressed in human hepatocellular carcinoma, and their expression levels are often correlated with patient prognosis. Moreover, preclinical studies have demonstrated that the inhibition of key cytokinesis regulators can suppress the growth of human hepatocellular carcinoma. Here, we provide an overview of the current understanding of the signaling networks regulating cytokinesis, the key cytokinesis regulators involved in the initiation and development of human hepatocellular carcinoma, and their applications as potential diagnostic and therapeutic biomarkers.
MittalSEl-SeragHB.Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol2013;
47: S2–6
2.
BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2018;
68:394–424
3.
ParkJWChenMColomboMRobertsLRSchwartzMChenPJKudoMJohnsonPWagnerSOrsiniLSShermanM.Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int2015;
35:2155–66
LlovetJM.Updated treatment approach to hepatocellular carcinoma. J Gastroenterol2005;
40:225–35
6.
IkedaMMorizaneCUenoMOkusakaTIshiiHFuruseJ.Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol2018;
48:103–14
7.
SarveazadAAgahSBabahajianAAminiNBahardoustM.Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci2019;
24:86
8.
BurkeDJChurchD.Protein synthesis requirements for nuclear division, cytokinesis, and cell separation in Saccharomyces cerevisiae. Mol Cell Biol1991;
11:3691–98
9.
Pickett-HeapsJDNorthcoteDH.Organization of microtubules and endoplasmic reticulum during mitosis and cytokinesis in wheat meristems. J Cell Sci1966;
1:109–20
10.
BarrFAGrunebergU.Cytokinesis: placing and making the final cut. Cell2007;
131:847–60
11.
DonneRSaroul-AïnamaMCordierPCelton-MorizurSDesdouetsC.Polyploidy in liver development, homeostasis and disease. Nat Rev Gastroenterol Hepatol2020;
17:391–405
12.
SchoenfelderKPFoxDT.The expanding implications of polyploidy. J Cell Biol2015;
209:485–91
13.
LuPProstSCaldwellHTugwoodJDBettonGRHarrisonDJ.Microarray analysis of gene expression of mouse hepatocytes of different ploidy. Mamm Genome2007;
18:617–26
14.
Bahar HalpernKTanamiSLandenSChapalMSzlakLHutzlerANizhbergAItzkovitzS.Bursty gene expression in the intact mammalian liver. Mol Cell2015;
58:147–56
15.
MiettinenTPPessaHKCaldezMJFuhrerTDirilMKSauerUKaldisPBjörklundM.Identification of transcriptional and metabolic programs related to mammalian cell size. Curr Biol2014;
24:598–608
16.
MatsumotoTWakefieldLPetersAPetoMSpellmanPGrompeM.Proliferative polyploid cells give rise to tumors via ploidy reduction. Nat Commun2021;
12:646
17.
Bou-NaderMCarusoSDonneRCelton-MorizurSCalderaroJGentricGCadouxML’HermitteAKleinCGuilbertTAlbuquerqueMCouchyGParadisVCoutyJ-PZucman-RossiJDesdouetsC.Polyploidy spectrum: a new marker in HCC classification. Gut2020;
69:355–64
18.
VermaVMogilnerA.Classical and emerging regulatory mechanisms of cytokinesis in animal cells. Biology2019;
8:55
19.
FededaJPGerlichDW.Molecular control of animal cell cytokinesis. Nat Cell Biol2012;
14:440–47
20.
NiiyaFTatsumotoTLeeKSMikiT.Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA. Oncogene2006;
25:827–37
21.
LeeK-YEsmaeiliBZealleyBMishimaM.Direct interaction between centralspindlin and PRC1 reinforces mechanical resilience of the central spindle. Nat Commun2015;
6:7290
22.
KimHGuoFBrahmaSXingYBurkardME.Centralspindlin assembly and 2 phosphorylations on MgcRacGAP by polo-like kinase 1 initiate Ect2 binding in early cytokinesis. Cell Cycle2014;
13:2952–61
23.
Neef Rd PreisingerCSutcliffeJKopajtichRNiggEAMayerTUBarrFA.Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis. J Cell Biol2003;
162:863–76
24.
CarmenaMWheelockMFunabikiHEarnshawWC.The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol2012;
13:789–803
25.
KitagawaMLeeSH.The chromosomal passenger complex (CPC) as a key orchestrator of orderly mitotic exit and cytokinesis. Front Cell Dev Biol2015;
3:14
26.
ZaytsevAVSegura-PeñaDGodziMCalderonABallisterERStamatovRMayoAMPetersonLBlackBEAtaullakhanovFILampsonMAGrishchukEL.Bistability of a coupled Aurora B kinase-phosphatase system in cell division. Elife2016;
5:e10644
27.
WheatleySPHinchcliffeEHGlotzerMHymanAASluderG.WangYlCDK1 inactivation regulates anaphase spindle dynamics and cytokinesis in vivo. J Cell Biol1997;
138:385–93
28.
BasantAGlotzerM.Spatiotemporal regulation of RhoA during cytokinesis. Curr Biol2018;
28:R570–R80
29.
LaporteDZhaoRWuJ-Q.Mechanisms of contractile-ring assembly in fission yeast and beyond. Semin Cell Dev Biol2010;
21:892–98
30.
WernerMMunroEGlotzerM.Astral signals spatially bias cortical myosin recruitment to break symmetry and promote cytokinesis. Curr Biol2007;
17:1286–97
31.
DekrakerCBoucherEMandatoCA.Regulation and assembly of actomyosin contractile rings in cytokinesis and cell repair. Anat Rec2018;
301:2051–66
32.
HicksonGRXO'FarrellPH.Anillin: a pivotal organizer of the cytokinetic machinery. Biochem Soc Trans2008;
36:439–41
33.
MishraMKashiwazakiJTakagiTSrinivasanRHuangYBalasubramanianMKMabuchiI.In vitro contraction of cytokinetic ring depends on myosin II but not on actin dynamics. Nat Cell Biol2013;
15:853–59
34.
MatsumuraF.Regulation of myosin II during cytokinesis in higher eukaryotes. Trends Cell Biol2005;
15:371–77
35.
KhaliullinRNGreenRAShiLZGomez-CavazosJSBernsMWDesaiA.A positive-feedback-based mechanism for constriction rate acceleration during cytokinesis in Caenorhabditis elegans. Elife2018;
7:e36073
36.
SunLGuanRLeeIJLiuYChenMWangJWuJ-QChenZ.Mechanistic insights into the anchorage of the contractile ring by anillin and Mid1. Dev Cell2015;
33:413–26
37.
LekomtsevSSuKCPyeVEBlightKSundaramoorthySTakakiTCollinsonLMCherepanovPDivechaNPetronczkiM.Centralspindlin links the mitotic spindle to the plasma membrane during cytokinesis. Nature2012;
492:276–9
CastedoMCoquelleAVivetSVitaleIKauffmannADessenPPequignotMOCasaresNValentAMouhamadSSchmittEModjtahediNVainchenkerWZitvogelLLazarVGarridoCKroemerG.Apoptosis regulation in tetraploid cancer cells. EMBO J2006;
25:2584–95
41.
ShenY-JDeLongCJTercéFKuteTWillinghamMCPettenatiMJCuiZ.Polyploid formation via chromosome duplication induced by CTP:Phosphocholine cytidylyltransferase deficiency and bcl-2 overexpression: identification of two novel endogenous factors. J Histochem Cytochem2005;
53:725–33
42.
CastedoMCoquelleAVitaleIVivetSMouhamadSViaudSZitvogelLKroemerG.Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis. Ann N Y Acad Sci2006;
1090:35–49
43.
DewhurstSMMcGranahanNBurrellRARowanAJGrönroosEEndesfelderDJoshiTMouradovDGibbsPWardRLHawkinsNJSzallasiZSieberOMSwantonC.Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov2014;
4:175
44.
GönczyP.Centrosomes and cancer: revisiting a long-standing relationship. Nat Rev Cancer2015;
15:639–52
45.
GodinhoSAKwonMPellmanD.Centrosomes and cancer: how cancer cells divide with too many centrosomes. Cancer Metastasis Rev2009;
28:85–98
46.
StorchovaZPellmanD.From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol2004;
5:45–54
47.
CastedoMSenovillaLVitaleIKroemerG.Tetraploid cancer cell precursors in ovarian carcinoma. Cell Cycle2012;
11:3157–58
48.
DuijfPHGSchultzNBenezraR.Cancer cells preferentially lose small chromosomes. Int J Cancer2013;
132:2316–26
49.
ChaisaingmongkolJBudhuADangHRabibhadanaSPupacdiBKwonSMForguesMPomyenYBhudhisawasdiVLertprasertsukeNChotirosniramitAPairojkulCAuewarakulCUSricharunratTPhornphutkulKSangrajrangSCamMHePHewittSMYlayaKWuXAndersenJBThorgeirssonSSWaterfallJJZhuYJWallingJStevensonHSEdelmanDMeltzerPSLoffredoCAHamaNShibataTWiltroutRHHarrisCCMahidolCRuchirawatMWangXW.Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell2017;
32:57–70.e3
50.
JinJXuHLiWXuXLiuHWeiF.LINC00346 acts as a competing endogenous RNA regulating development of hepatocellular carcinoma via modulating CDK1/CCNB1 axis. Front Bioeng Biotechnol2020;
8:54
51.
ZhangXWangLYanY.Identification of potential key genes and pathways in hepatitis B virus-associated hepatocellular carcinoma by bioinformatics analyses. Oncol Lett2020;
19:3477–86
52.
YangWXPanYYYouCG.CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 may be potential therapeutic targets for hepatocellular carcinoma using integrated bioinformatic analysis. Biomed Res Int2019;
2019:1245072
53.
WuMLiuZLiXZhangALinDLiN.Analysis of potential key genes in very early hepatocellular carcinoma. World J Surg Oncol2019;
17:77
54.
BrownNRKorolchukSMartinMPStanleyWAMoukhametzianovRNobleMEMEndicottJA.CDK1 structures reveal conserved and unique features of the essential cell cycle CDK. Nat Commun2015;
6:6769
55.
DanhierFUcakarBMagotteauxNBrewsterMEPréatV.Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Int J Pharm2010;
392:20–8
LiLHuangKZhaoHChenBYeQYueJ.CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma. Cell Cycle2020;
19:1236–52
58.
ShaoYYLiYSHsuHWLinHWangHYWoRRChengALHsuCH.Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinoma. Cancers2019;
11:1433
59.
WangYShiFXingGHXiePZhaoNYinYFSunSYHeJWangYXuanSY.Protein regulator of cytokinesis PRC1 confers chemoresistance and predicts an unfavorable postoperative survival of hepatocellular carcinoma patients. J Cancer2017;
8:801–08
60.
ChenJRajasekaranMXiaHZhangXKongSNSekarKSeshachalamVPDeivasigamaniAGohBKOoiLLHongWHuiKM.The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the wnt/β-catenin signalling pathway. Gut2016;
65:1522–34
61.
LiuXLiYMengLLiuXYPengAChenYLiuCChenHSunSMiaoXZhangYZhengLHuangK.Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma. Cell Death Dis2018;
9:534
62.
ZhuCZhaoJBibikovaMLeversonJDBossy-WetzelEFanJ-BAbrahamRTJiangW.Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell2005;
16:3187–99
63.
HuangYWangHLianYWuXZhouLWangJDengMHuangY.Upregulation of kinesin family member 4A enhanced cell proliferation via activation of akt signaling and predicted a poor prognosis in hepatocellular carcinoma. Cell Death Dis2018;
9:141
64.
ChenJLiSZhouSCaoSLouYShenHYinJLiG.Kinesin superfamily protein expression and its association with progression and prognosis in hepatocellular carcinoma. J Cancer Res Ther2017;
13:651–59
65.
GlotzerM.The molecular requirements for cytokinesis. Science2005;
307:1735–9
66.
SunXJinZSongXWangJLiYQianXZhangYYinY.Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma. BMC Cancer2015;
15:961
67.
ZhangBHYangJJiangLLyuTKongLXTanYFLiBZhuYFXiAYXuXYanLNYangJY.Development and validation of a 14-gene signature for prognosis prediction in hepatocellular carcinoma. Genomics2020;
112:2763–71
68.
KitagawaMFungSYOnishiNSayaHLeeSH.Targeting Aurora B to the equatorial cortex by MKlp2 is required for cytokinesis. PLoS One2013;
8:e64826
69.
GasnereauIBoissanMMargall-DucosGCouchyGWendumDBourgain-GuglielmettiFDesdouetsCLacombeMLZucman-RossiJSobczak-ThépotJ.KIF20A mRNA and its product MKlp2 are increased during hepatocyte proliferation and hepatocarcinogenesis. Am J Pathol2012;
180:131–40
70.
LuMHuangXChenYFuYXuCXiangWLiCZhangSYuC.Aberrant KIF20A expression might independently predict poor overall survival and recurrence-free survival of hepatocellular carcinoma. IUBMB Life2018;
70:328–35
71.
KawaiYShibataKSakataJSuzukiSUtsumiFNiimiKSekiyaRSengaTKikkawaFKajiyamaH.KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear‑cell carcinoma cells. Oncol Rep2018;
40:195–205
72.
RaabMSanhajiMMatthessYHörlinALorenzIDötschCHabbeNWaidmannOKurunci-CsacskoEFiresteinRBeckerSStrebhardtK.PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. Nat Commun2018;
9:1106
73.
HeZLZhengHLinHMiaoXYZhongDW.Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol2009;
15:4177–82
74.
SunWSuQCaoXShangBChenAYinHLiuB.High expression of polo-like kinase 1 is associated with early development of hepatocellular carcinoma. Int J Genom2014;
2014:312130
75.
WangXQZhuYQLuiKSCaiQLuPPoonRT.Aberrant polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma. Clin Cancer Res2008;
14:6813–20
76.
KumarSKimJ.PLK-1 targeted inhibitors and their potential against tumorigenesis. BioMed Res Int2015;
2015:705745–45
77.
KoMARosarioCOHudsonJWKulkarniSPollettADennisJWSwallowCJ.Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet2005;
37:883–8
78.
RosarioCOKoMAHaffaniYZGladdyRAPaderovaJPollettASquireJADennisJWSwallowCJ.Plk4 is required for cytokinesis and maintenance of chromosomal stability. Proc Natl Acad Sci U S A2010;
107:6888–93
79.
BaoJYuYChenJHeYChenXRenZXueCLiuLHuQLiJCuiGSunR.MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis2018;
9:1045
80.
MengLZhouYJuSHanJSongCKongJWuYLuSXuJYuanWZhangEWangCHuZ.A cis-eQTL genetic variant in PLK4 confers high risk of hepatocellular carcinoma. Cancer Med2019;
8:6476–84
81.
HollandAJLanWNiessenSHooverHClevelandDW.Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability. J Cell Biol2010;
188:191–8
82.
PortellaGPassaroCChieffiP.Aurora B: a new prognostic marker and therapeutic target in cancer. Curr Med Chem2011;
18:482–96
83.
TovuuLOUtsunomiyaTImuraSMorineYIkemotoTArakawaYMoriHHanaokaJKanamotoMSugimotoKSaitoYYamadaSAsanomaMShimadaM.The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma. Int J Clin Oncol2014;
19:622–8
84.
LinZZJengYMHuFCPanHWTsaoHWLaiPLLeePHChengALHsuHC.Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B overexpression in HCC. BMC Cancer2010;
10:461
85.
SistayanarainATsuneyamaKZhengHTakahashiHNomotoKChengCMuraiYTanakaATakanoY.Expression of Aurora-B kinase and phosphorylated histone H3 in hepatocellular carcinoma. Anticancer Res2006;
26:3585–93
86.
TanakaSAriiSYasenMMogushiKSuNTZhaoCImotoIEishiYInazawaJMikiYTanakaH.Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg2008;
95:611–9
87.
FuSLiYHuangJLiuTHongZChenABastRCKavanaghJJGershensonDMSoodAKHuW.Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther2012;
13:1034–41
88.
MortlockAAFooteKMHeronNMJungFHPasquetGLohmannJJWarinNRenaudFDe SaviCRobertsNJJohnsonTDoussonCBHillGBPerkinsDHatterGWilkinsonRWWedgeSRHeatonSPOdedraRKeenNJCrafterCBrownEThompsonKBrightwellSKhatriLBradyMCKearneySMcKillopDRheadSParryTGreenS.Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase. J Med Chem2007;
50:2213–24
89.
GilesFJSwordsRTNaglerAHochhausAOttmannOGRizzieriDATalpazMClarkJWatsonPXiaoAZhaoBBergstromDLe CoutrePDFreedmanSJCortesJE.MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia2013;
27:113–7
90.
YuXLiangQLiuWZhouLLiWLiuH.Deguelin, an Aurora B kinase inhibitor, exhibits potent anti-Tumor effect in human esophageal squamous cell carcinoma. EBioMedicine2017;
26:100–11
91.
LiZRenWZengQChenSZhangMZhaoYChengJWangX.Effects of survivin on angiogenesis in vivo and in vitro. Am J Transl Res2016;
8:270–83
92.
ItoTShirakiKSugimotoKYamanakaTFujikawaKItoMTakaseKMoriyamaMKawanoHHayashidaMNakanoTSuzukiA.Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology2000;
31:1080–5
93.
XiaHChenJShiMDeivasigamaniAOoiLLHuiKM.The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma. Oncotarget2015;
6:5990–6000
94.
WeiWWanjunLHuiSDongyueCXinjunYJishengZ.miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell Biochem Funct2013;
31:82–5
95.
YamauchiTNakamuraNHiramotoMYuriMYokotaHNaitouMTakeuchiMYamanakaKKitaANakaharaTKinoyamaIMatsuhisaAKanekoNKoutokuHSasamataMKoboriMKatouMTawaraSKawabataSFuruichiK.Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun2012;
425:711–6
96.
ShimizuTNishioKSakaiKOkamotoIOkamotoKTakedaMMorishitaMNakagawaK.Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer. Cancer Chemother Pharmacol2020;
86:211–19
97.
ZhaoXOgunwobiOOLiuC.Survivin inhibition is critical for bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. PLoS One2011;
6:e21980
98.
YinHQueRLiuCJiWSunBLinXZhangQZhaoXPengZZhangXQianHChenLYaoYSuC.Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma. Cancer Lett2018;
425:54–64
99.
YueLLiLLiDYangZHanSChenMLanSXuXHuiL.High-throughput screening for survivin and borealin interaction inhibitors in hepatocellular carcinoma. Biochem Biophys Res Commun2017;
484:642–47
100.
BaldwinELOsheroffN.Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents2005;
5:363–72
101.
ChenJXiaHZhangXKarthikSPratapSVOoiLLHongWHuiKM.ECT2 regulates the rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma. J Hepatol2015;
62:1287–95
102.
YuYCaiOWuPTanS.MiR-490-5p inhibits the stemness of hepatocellular carcinoma cells by targeting ECT2. J Cell Biochem2019;
120:967–76
103.
GalloG.RhoA-kinase coordinates F-actin organization and myosin II activity during semaphorin-3A-induced axon retraction. J Cell Sci2006;
119:3413–23
104.
WangDDouKXiangHSongZZhaoQChenYLiY.Involvement of RhoA in progression of human hepatocellular carcinoma. J Gastroenterol Hepatol2007;
22:1916–20
105.
LiXRJiFOuyangJWuWQianLYYangKY.Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma. Eur J Surg Oncol2006;
32:1130–4
106.
BaiYXieFMiaoFLongJHuangSHuangHLinJWangDYangXBianJMaoJWangXMaoYSangXZhaoH.The diagnostic and prognostic role of RhoA in hepatocellular carcinoma. Aging2019;
11:5158–72
107.
WangFXuXZhangNChenZ.Identification and integrated analysis of hepatocellular carcinoma-related circular RNA signature. Ann Transl Med2020;
8:294
108.
YinKZhaoGHuangXGaoGSunHWeiQLiuQLiMXuCZhuSBaZYanG.Inhibition of RhoA expression by adenovirus-mediated siRNA combined with TNF-α induced apoptosis of hepatocarcinoma cells. Bio Med Mater Eng2015;
26:S2055–67
109.
ZhangYDengJMaSXueLZhuJZhuWLJiangHLLiJMiaoLY.The effect of first-in-class small molecule RhoA inhibitor, HL07, on the phenylephrine-induced artery contraction. Curr Pharm Des2012;
18:4258–64
110.
ShangXMarchioniFEvelynCRSipesNZhouXSeibelWWortmanMZhengY.Small-molecule inhibitors targeting G-protein-coupled rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A2013;
110:3155–60
111.
PietrovitoLComitoGParriMGiannoniEChiarugiPTaddeiML.Zoledronic acid inhibits the RhoA-mediated amoeboid motility of prostate cancer cells. Curr Cancer Drug Targets2019;
19:807–16
112.
EvelynCRWadeSMWangQWuMIñiguez-LluhíJAMerajverSDNeubigRR.CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther2007;
6:2249–60
113.
KatamuraYAikataHHashimotoYKimuraYKawaokaTTakakiSWakiKHiramatsuAKawakamiYTakahashiSKenjoMChayamaK.Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma. Hepatol Res2010;
40:1195–203
114.
HondaYAikataHHondaFNakanoNNakamuraYHatookaMMorioKKobayashiTFukuharaTNagaokiYKawaokaTHiramatsuAImamuraMKawakamiYChayamaK.Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid. Hepatol Res2017;
47:1053–60
115.
NatoriTYamaguchiM. [
Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis – a case report. Gan to Kagaku Ryoho Cancer Ryoho2013;
40:635–7
116.
WangSMOoiLLHuiKM.Upregulation of rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res2011;
17:6040–51
117.
YangXMCaoXYHePLiJFengMXZhangYLZhangXLWangYHYangQZhuLNieHZJiangSHTianGAZhangXXLiuQJiJZhuXXiaQZhangZG.Overexpression of rac GTPase activating protein 1 contributes to proliferation of cancer cells by reducing hippo signaling to promote cytokinesis. Gastroenterology2018;
155:1233–49e22
118.
WangMYChenDPQiBLiMYZhuYYYinWJHeLYuYLiZYLinLYangFLinZRLiuJQ.Pseudogene RACGAP1P activates RACGAP1/rho/ERK signalling axis as a competing endogenous RNA to promote hepatocellular carcinoma early recurrence. Cell Death Dis2019;
10:426
119.
SantamaríaDBarrièreCCerqueiraAHuntSTardyCNewtonKCáceresJFDubusPMalumbresMBarbacidM.Cdk1 is sufficient to drive the mammalian cell cycle. Nature2007;
448:811–5
120.
PotapovaTADaumJRByrdKSGorbskyGJ.Fine tuning the cell cycle: activation of the Cdk1 inhibitory phosphorylation pathway during mitotic exit. Mol Biol Cell2009;
20:1737–48
121.
WuCXWangXQChokSHManKTsangSHYChanACYMaKWXiaWCheungTT.Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics2018;
8:3737–50
122.
TangHZhaoHYuZYFengXFuBSQiuCHZhangJW.MicroRNA-194 inhibits cell invasion and migration in hepatocellular carcinoma through PRC1-mediated inhibition of wnt/β-catenin signaling pathway. Dig Liver Dis2019;
51:1314–22
123.
HirokawaNNodaYTanakaYNiwaS.Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol2009;
10:682–96
124.
FerreroHCorachánAQuiñoneroABougeretCPoulettyPPellicerADomínguezF.Inhibition of KIF20A by BKS0349 reduces endometriotic lesions in a xenograft mouse model. Mol Hum Reprod2019;
25:562–71
125.
GrayPJJr.BearssDJHanHNagleRTsaoMSDeanNVon HoffDD.Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther2004;
3:641–6
126.
WolfGElezRDoermerAHoltrichUAckermannHStutteHJAltmannsbergerHMRübsamen-WaigmannHStrebhardtK.Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene1997;
14:543–9
127.
KingSIPurdieCABraySEQuinlanPRJordanLBThompsonAMMeekDW.Immunohistochemical detection of polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome. Breast Cancer Res2012;
14:R40
128.
WeichertWKristiansenGSchmidtMGekelerVNoskeANiesporekSDietelMDenkertC.Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol2005;
11:5644–50
129.
LiuZSunQWangX.PLK1, a potential target for cancer therapy. Transl Oncol2017;
10:22–32
130.
de CárcerGVenkateswaranSV.Plk1 overexpression induces chromosomal instability and suppresses tumor development. Nat Commun2018;
9:3012
131.
DöhnerHLübbertMFiedlerWFouillardLHaalandABrandweinJMLepretreSRemanOTurlurePOttmannOGMüller-TidowCKrämerARaffouxEDöhnerKSchlenkRFVossFTaubeTFritschHMaertensJ.Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood2014;
124:1426–33
132.
PressMFXieBDavenportSZhouYGuzmanRNolanGPO'BrienNPalazzoloMMakTWBruggeJSSlamonDJ.Role for polo-like kinase 4 in mediation of cytokinesis. Proc Natl Acad Sci U S A2019;
116:11309–18
133.
ZhaoYWangX.PLK4: a promising target for cancer therapy. J Cancer Res Clin Oncol2019;
145:2413–22
134.
HindriksenSMeppelinkALensSM.Functionality of the chromosomal passenger complex in cancer. Biochem Soc Trans2015;
43:23–32
135.
KrennVMusacchioA.The Aurora B kinase in chromosome bi-orientation and spindle checkpoint signaling. Front Oncol2015;
5:225
136.
BentenDKellerGQuaasASchraderJGontarewiczABalabanovSBraigMWegeHMollJLohseAWBrummendorfTH.Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia2009;
11:934–44
137.
VaderGKauwJJMedemaRHLensSM.Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep2006;
7:85–92
138.
WheatleySPAltieriDC.Survivin at a glance. J Cell Sci2019;
132:jcs223826
139.
ChangYJLiLTChenHAHungCSWeiPL.Silencing survivin activates autophagy as an alternative survival pathway in HCC cells. Tumour Biol2014;
35:9957–66
140.
LiuFSunYLiuBLuJLiHZhuHGaoHZhouXChangH.Insulin-like growth factor-1 induces epithelial-mesenchymal transition in hepatocellular carcinoma by activating survivin. Oncol Rep2018;
40:952–58
141.
BeyerTESmithRMSongZGokhaleVMosesSAMeuilletEJ.Abstract 2835: discovery of novel inhibitors for ECT2 as a novel therapeutic strategy for lung cancer. Cancer Res2012;
72:2835
142.
SitS-TManserE.Rho GTPases and their role in organizing the actin cytoskeleton. J Cell Sci2011;
124:679–83
143.
KühnSGeyerM.Formins as effector proteins of rho GTPases. Small GTPases2014;
5:e29513
144.
van AdrichemAJFagerholmATurunenLLehtoASaarelaJKoskinenARepaskyGAWennerbergK.Discovery of MINC1, a GTPase-activating protein small molecule inhibitor, targeting MgcRacGAP. Comb Chem High Throughput Screen2015;
18:3–17
145.
GargHSuriPGuptaJCTalwarGPDubeyS.Survivin: a unique target for tumor therapy. Cancer Cell Int2016;
16:49
146.
XuDWangYWuJZhangZChenJXieMTangRChenCChenLLinSLuoXZhengJ.ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2/PLK1/PTEN pathway. Cell Death Dis2021;
12:162
147.
KimJALeeJMargolisRLFotedarR.SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene2010;
29:1702–16
